

Clinical Trial: NCT01533207

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

DOI: 10.1200/JCO.18.00454

PMID: 30289732

Data as of: December 4, 2017

File: NCT01533207-D1-Dataset.csv

NOTES:

Two patients with zero follow-up time excluded from KM Analysis in publication.

Variable	Type	Label
patid_blind	Char	Blinded Patient Identifier
nrxn	Num	Randomized Treatment Assignment
	Value	Label
	1	Gem/Doc-->Dox
	2	Observation
nonprotn	Num	Indicator for Nonprotocol Therapy Before Disease Recurrence
	Value	Label
	0	No
	1	Yes
agecatn	Num	Age Group
	Value	Label
	1	30-39 Years
	2	40-49 Years
	3	50-59 Years
	4	60-69 Years
	5	70-79 Years
countryn	Num	Country (Levels combined for patient privacy)
	Value	Label

1	United States
2	Other

ethnicn	Value	Num	Label	Ethnicity (Levels combined for patient privacy)
	1		Other	
	2		Non-Hispanic	

racen	Value	Num	Label	Race (Levels combined for patient privacy)
	1		White	
	2		Black/African American	
	3		Other	

stagen	Value	Num	Label	Stage
	1		1	
	2		1A	
	3		1B	

coursesn	Num	Study Treatment Courses
		Periods denote undefined course information for patients randomized to Observation.

whyoffn	Value	Num	Label	Off Study Reason
	1		Routine, completed study treatment	
	2		Disease progression	
	3		Refused further study treatment	
	5		Toxicity not specifically permitted in protocol	
	8		Other	

survstat	Value	Num	Label	Overall Survival Status
	1		Alive	
	2		Dead	

survtime	Num	Overall Survival Time (Months)
----------	-----	--------------------------------

pfstat	Value	Num	Label	Progression-Free Survival Status
	1		No recurrence	
	2		Recurrence	

pfstime Num Progression-Free Survival Time (Months)

recurlocln Num Recurrence Location

Value	Label
.	Missing value
1	Distant
2	Local/Pelvic
